SCHEMBL8814964

SCHEMBL8814964

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)Oc1ccccc1C(=O)O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.73
MEN1 O00255 2/20 0.73
RECQL P46063 2/20 0.73
KMT2A Q03164 2/20 0.73
POLM Q9NP87 1/20 0.53
POLK Q9UBT6 1/20 0.53
POLL Q9UGP5 1/20 0.53
POLH Q9Y253 1/20 0.53
ALDH1A1 P00352 3/20 0.52
MAPT P10636 3/20 0.52
FAAH O00519 3/20 0.52
HPGD P15428 2/20 0.52
CNR1 P21554 2/20 0.52
CNR2 P34972 1/20 0.52
PPARG P37231 3/20 0.51
USP2 O75604 1/20 0.51
LMNA P02545 1/20 0.51
TP53 P04637 1/20 0.51
CYP3A4 P08684 1/20 0.51
HSPD1 P10809 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8814970 1.00 KDM4E (0.73) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL16800410 1.00 KDM4E (0.73) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL469664 0.97 KDM4E (0.73) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL8439129 0.97 KDM4E (0.73) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL16800411 0.96 KDM4E (0.71) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL17369041 0.96 KDM4E (0.71) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL17369039 0.94 KDM4E (0.75) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL7710665 0.94 KDM4E (0.75) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL454163 0.94 KDM4E (0.75) KDM4EMEN1RECQLKMT2APOLM
SCHEMBL16800397 0.91 KDM4E (0.67) KDM4EMEN1RECQLKMT2APOLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150374839-A1 NOVEL FATTY ACID-SALICYLATE CONJUGATES WITH ENHANCED THERAPEUTIC PROPERTIES KEAN UNIVERSITY (US) 2015-12-31 US disclosed
US-20150374839-A1 NOVEL FATTY ACID-SALICYLATE CONJUGATES WITH ENHANCED THERAPEUTIC PROPERTIES KEAN UNIVERSITY (US) 2015-12-31 US disclosed
US-9056139-B2 Fatty acid-salicylate conjugates with enhanced therapeutic properties KEAN UNIVERSITY (US) 2015-06-16 US disclosed
US-9056139-B2 Fatty acid-salicylate conjugates with enhanced therapeutic properties KEAN UNIVERSITY (US) 2015-06-16 US disclosed
WO-1997020212-A1 TREATMENT OF INFLAMMATION BY INHIBITION OF LIPID BODY FORMATION BETH ISRAEL DEACONESS MEDICAL CENTER (US) 1997-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150374839-A1 NOVEL FATTY ACID-SALICYLATE CONJUGATES WITH ENHANCED THERAPEUTIC PROPERTIES FASN, ELOVL1, ELOVL3 KDM4E 2152/4885MEN1 4457/4885RECQL 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.